Gamida Cell (GMDA) Company Overview

TORONTO and HAIFA, Israel, June 21, 2024 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX), (OTCQB: NRXBF), (Germany: J90) (the “Company” or “NurExone”), a pioneering biopharmaceutical company, welcomes Dr. Yona Geffen, as a consultant, to support the Company's preclinical and clinical activities. Dr. Geffen, who currently serves as Vice President of Research and Development at Gamida Cell Ltd. (“Gamida Cel l”), brings over two decades of extensive experience in leading clinical and drug development in the biotechnology and pharmaceutical industries. Under her leadership, Gamida Cell obtained United States Food and Drug Administration approval for Omisirge®, a groundbreaking stem cell therapy.

Gamida Cell (NASDAQ: GMDA ) stock is falling hard on Wednesday after the clinical-stage biopharmaceutical company announced major changes to its business in its Q4 earnings report. This big news here is the company entering into a Restructuring Support Agreement (RSA) with funds managed by Highbridge Capital Management.

BOSTON, Nov. 20, 2023 (GLOBE NEWSWIRE) -- Gamida Cell Ltd. (Nasdaq: GMDA), a cell therapy pioneer working to turn cells into powerful therapeutics, today announced that its management team will present corporate highlights at the upcoming Piper Sandler 35th Annual Healthcare Conference in New York, NY.

Gamida Cell's approved therapy, Omisirge, shows faster neutrophil recovery and reduced infections in blood cancer patients compared to standard care. The long-term study of Omisirge includes a diverse patient population, improving its marketability. Cash headwinds continue to be a challenge, and their latest financial filings do not ease this uncertainty.

Gamida Cell Ltd. (GMDA) is looking like an interesting pick from a technical perspective, as the company reached a key level of support.

Gamida Cell Ltd. (NASDAQ:GMDA ) Q1 2023 Results Conference Call May 15, 2023 4:30 PM ET Company Participants Mike Kuczkowski - Corporate Communications Abbey Jenkins - President and CEO Michele Korfin - COO and Chief Commercial Officer Ronit Simantov - Chief Medical Officer and Scientific Officer Shai Lankry - CFO Conference Call Participants Edward Tenthoff - Piper Sandler Gil Blum - Needham & Company Vernon Bernardino - H.C.

BOSTON--(BUSINESS WIRE)--Gamida Cell Ltd. (Nasdaq: GMDA), a cell therapy pioneer working to turn cells into powerful therapeutics, today announced that the company will host a conference call and live audio webcast on Monday, May 15, 2023, at 4:30 p.m. ET to review its first quarter 2023 financial results and provide an update on the company. To access the conference call, please register here and be advised to do so at least 10 minutes prior to joining the call. A live webcast of the conferenc.

Gamida Cell (NASDAQ: GMDA ) stock is falling on Wednesday after the cell therapy company revealed details of a public securities offering. According to a press release from the company, it is selling both shares of GMDA stock, as well as warrants to purchase shares of its stock.

Gamida Cell Ltd. (NASDAQ: GMDA) is an Israeli-based developmental biotechnology company specializing in discovering and advancing cell therapies to fight blood cancer and other illnesses.